Princeton, NJ – November 23, 2021– Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging, is pleased to be exhibiting in Booth 1711 at the RSNA 2021 Scientific Assembly and Annual Meeting and to share its continued partnership with the Radiological Society of North America (RSNA) through the awarding of its Guerbet Research Scholar Grant. After a thorough review of hundreds of grant applications, the RSNA Research & Education (R&E) Foundation Board of Trustees awarded $3.2 million in funding to Hersh Sagreiya, MD, with the University of Pennsylvania, to pursue research on Automated Hepatic Fat Quantification Using Machine Learning.
“As a corporate donor through RSNA’s R&E Vanguard program, we are proud to help promote the work of Dr. Sagreiya and his colleagues,” said Thomas McLaughlin, VP, Guerbet North America. “Guerbet is committed to advancing, empowering, and advocating for our shared radiological industry and are proud to partner with RSNA to grant funds that will help us further understand the intersections between health, technology, and treatment.”
The RSNA R&E Foundation invests in the future of radiology by developing investigators and supporting lifelong innovative research and education. Guerbet is equally committed to this cause, which is why the company continues to be an industry leader in promoting grant and partnership programs, including:
Along with these key opportunities, Guerbet also collaborates across the industry to promote awareness and celebrate those who care for patients. Guerbet is pleased to have partnered with AHRA for over five years to support their Defining Our Future Campaign. In addition, Guerbet has regularly participated in ASRT’s National Radiologic Technology Week (NRTW).
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. This is our purpose. We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging. A pioneer since 95 years in the field of contrast media with over 2,600 people globally, we are continuously innovating with 10% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €712 million in revenue in 2020. For more information, please visit www.guerbet-us.com
Media relations
Kelly Starkey + 435.901.3278 + kelly@starkeyconsulting.com